Addus HomeCare (ADUS) Stock Price, News & Analysis

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Addus HomeCare in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ADUS shares.
View ADUS analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 1 year price targets for Addus HomeCare's shares. Their ADUS share price targets range from $88.00 to $118.00. On average, they predict the company's share price to reach $103.83 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price.
View analysts price targets for ADUS or view top-rated stocks among Wall Street analysts.

Addus HomeCare's stock was trading at $92.85 at the beginning of 2024. Since then, ADUS stock has increased by 4.1% and is now trading at $96.62.
View the best growth stocks for 2024 here.

Addus HomeCare saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 354,100 shares, a drop of 9.9% from the March 15th total of 393,100 shares. Based on an average trading volume of 113,700 shares, the days-to-cover ratio is currently 3.1 days. Currently, 2.2% of the shares of the stock are short sold.
View Addus HomeCare's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our ADUS earnings forecast.

Addus HomeCare Co. (NASDAQ:ADUS) announced its quarterly earnings results on Monday, February, 26th. The company reported $1.21 EPS for the quarter, topping the consensus estimate of $1.04 by $0.17. The business had revenue of $276.35 million for the quarter, compared to analysts' expectations of $274.02 million. Addus HomeCare had a net margin of 5.91% and a trailing twelve-month return on equity of 9.70%.

ETFs with the largest weight of Addus HomeCare (NASDAQ:ADUS) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap Health Care ETF (PSCH), Argent Mid Cap ETF (AMID), BNY Mellon Women's Opportunities ETF (BKWO) and Texas Capital Texas Equity Index ETF (TXS).iShares U.S. Healthcare Providers ETF (IHF).

91 employees have rated Addus HomeCare Chief Executive Officer Dirk Allison on Glassdoor.com. Dirk Allison has an approval rating of 51% among the company's employees. This puts Dirk Allison in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Addus HomeCare investors own include AbbVie (ABBV), Bank of America (BAC), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Verizon Communications (VZ), CVS Health (CVS), Pfizer (PFE), Ulta Beauty (ULTA), Cisco Systems (CSCO) and Walt Disney (DIS).

Addus HomeCare's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bridge City Capital LLC (0.19%), Los Angeles Capital Management LLC (0.06%), Guidance Capital Inc. (0.03%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Brian Poff, Darby Anderson, David W Tucker, Esteban Lopez, Michael D Wattenbarger, Monica Raines, R Dirk Allison, Roberton James Stevenson, Sean Gaffney and W Bradley Bickham.
View institutional ownership trends.

Shares of ADUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.